Mereo Biopharma Group (MREO) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $0.8m from the Sentynl alvelestat option fee; net loss narrowed to $5.9m from $7.0m YoY as operating expenses declined.

• Cash was $26.1m at September 30, 2026, and current plans project funding into late 2027; additional funding or cash conservation may be needed longer term.

Financial highlights

• Q3 revenue was $0.8m versus none in Q3 2025; 9M revenue was $0.8m versus $0.5m, including a one-time ReproNovo milestone in 2025.

• Q3 R&D was $2.1m versus $4.3m and G&A was $4.9m versus $6.0m; 9M R&D was $8.6m versus $13.6m and G&A was $14.2m versus $18.8m.

• Q3 net loss was $5.9m versus $7.0m; 9M net loss was $19.6m versus $34.5m and operating loss was $22.0m versus $31.7m.

• Cash and cash equivalents were $26.1m at September 30, 2026, versus $41.0m at December 31, 2025.

Outlook and guidance

• Current cash is expected to fund committed clinical trials, operating expenses and capital requirements into late 2027; estimates exclude potential business-development payments and may require additional funding or cash conservation.

• Alvelestat Phase 3 initiation is targeted for early 2027; study design is being refined with Sentynl and the FDA, with an update based on FDA interactions expected before year-end 2026.

• Setrusumab regulatory discussions with Ultragenyx are assessing data needed for a filing and whether a pediatric OI path forward exists; significant operating losses are expected as development continues.